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INTRODUCTION
The introduction of highly active antiretroviral therapy
(HAART) in the treatment of human immunodeficiency virus
type 1 (HIV-1) has led to marked improvement in morbidity
and mortality associated with HIV-1 infection (1). Howev-
er, treatment failure is inevitable in some patients with poor
adherence, adverse effects, and acquisition of a resistance to
antiretroviral drugs (2). Prospective data on resistance in pa-
tients with VF supports the concept that the virologic res-
ponses to therapy are better when the results of resistance
testing are available compared to the responses observed when
changes in therapy are guided only by clinical judgment only
(3, 4). Various aspects of genotypic resistance and clinical
application have been evaluated (5-9). However, some regional
factors can affect the selection of treatment, such as the avail-
ability of specific antiretroviral drugs especially in heavily
treatment-experienced patients. 
We believe it is worthwhile to reevaluate the benefits of
genotypic resistance assay in various regional conditions, and
this information might result in a better decision of treatment.
Actually, transmitted drug resistant strains were reported in
the Republic of Korea (10) as well as multi-drug resistant
strains in treatment experienced patients (11, 12). 
Since 2004, the Korea National Institute of Health has
offered HIV-1 genotypic resistance assay to practicing hos-
pitals. To assess the clinical influence obtained from resistance
testing in this area, we analyzed genotypic mutations asso-
ciated with antiretroviral resistance and observed virologic/
immunologic parameters after genotypic resistance assay and
HAART regimen change in Korean HIV-1 infected patients
with virologic failure (VF).
MATERIALS AND METHODS
Study population and data collection
From August 2004 to July 2006, 80 patients were referred
for genotypic resistance assay on account of VF. Among them,
we analyzed virologic and immunologic response for HAART
regimen change after genotypic resistance assay in 41 eligi-
ble patients with VF who satisfied following conditions: 1)
Patients who were taking HAART for more than 6 months
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Antiretroviral Genotypic Resistance Mutations in HIV-1 Infected Korean
Patients with Virologic Failure
Resistance assays are useful in guiding decisions for patients experiencing virologic
failure (VF) during highly-active antiretroviral therapy (HAART). We investigated
antiretroviral resistance mutations in 41 Korean human immunodeficiency virus type
1 (HIV-1) infected patients with VF and observed immunologic/virologic response
6 months after HAART regimen change. Mean HAART duration prior to resistance
assay was 45.3±27.5 months and commonly prescribed HAART regimens were
zidovudine/lamivudine/nelfinavir (22.0%) and zidovudine/lamivudine/efavirenz (19.5
%). Forty patients (97.6%) revealed intermediate to high-level resistance to equal or
more than 2 antiretroviral drugs among prescribed HAART regimen. M184V/I muta-
tion was observed in 36 patients (87.7%) followed by T215Y/F (41.5%) and M46I/L
(34%). Six months after resistance assay and HAART regimen change, median
CD4+ T cell count increased from 168 cells/μL (interquartile range [IQR], 62-253)
to 276 cells/μL (IQR, 153-381) and log viral load decreased from 4.65 copies/mL
(IQR, 4.18-5.00) to 1.91 copies/mL (IQR, 1.10-3.60) (P<0.001 for both values). The
number of patients who accomplished viral load <400 copies/mL was 26 (63.4%)
at 6 months follow-up. In conclusion, many Korean HIV-1 infected patients with VF
are harboring strains with multiple resistance mutations and immunologic/virologic
parameters are improved significantly after genotypic resistance assay and HAART
regimen change.
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when resistance assay was referred, 2) Patients with VF whose
viral load assay results revealed log values of ≥3 more than
twice during the 6 months prior to resistance assay referral,
3) Patients with available virologic and immunologic data
for at least 6 months after resistance assay. Patients with a
viral load of less than 1,000 copies/mL on resistance assay
referral were excluded, for such cases were regarded not suit-
able for resistance assay because of result reliability concerns
(13). Patients who did not change HAART regimen after
resistance assay were also excluded from analysis (Fig. 1). 
To comply with privacy concerns, a unique number system
was adopted by the public healthcare system for psychoso-
cial and financial support for people living with HIV/AIDS
in the Republic of Korea. We obtained age, sex, antiretrovi-
ral treatment history, CD4+ T cell count, and viral loads in
an anonymous data format from referring hospitals using this
number system. The resistance referral format also contained
information about the reason for resistance assay referral and
adequacy of compliance. 
Viral genotypic resistance assay
Viral genotypic resistance assay was performed with extract-
ed viral RNA using silica-binding nucleic acid extraction
(bioMe@rieux, Boxtel, The Netherlands). The polymerase chain
reaction (PCR) amplification conditions were based on the
Stanford Center for AIDS Research Laboratory protocol for
sequencing the protease and reverse transcriptase genes. Sequ-
encing reactions were performed using the ABI Prism Dye
Terminator Cycle Sequencing Ready Reaction Kit (Perkin-
Elmer, Wellesley, MA, U.S.A.) on an automated sequencer
(ABI Prism 3110 DNA sequencer). The pol gene sequences
of eligible patients were submitted to Genbank as accession
number EU290607-EU290646. Genotypic resistance muta-
tion analysis was performed using the HIV Drug Resistance
Database of Stanford University version 4.2.4 (http://hivdb.
stanford.edu/).
Drug resistance determination
According to the HIV Drug Resistance Database of Stanford
University, drug susceptibility was classified as ‘sensitive’ if
the summed drug-specific scores were 0-9; ‘potential low-level
resistance’ at 10-14; ‘low-level resistance’ at 15-29; ‘intermedi-
ate resistance’ at 30-59, and ‘high-level resistance’ at ≥60.
To determine the susceptibility of a specific drug, we classi-
fied the drugs as ‘susceptible’ when the interpretation by the
database was ‘sensitive’, ‘potential low-level resistance’, or ‘low-
level resistance’. We considered the drugs as ‘resistant’ for inter-
pretations of ‘intermediate resistance’ or ‘high-level resistance’.
Immunologic and virolgic data analysis
The CD4+ T cell count and log viral load were compared
between baseline and 6 months follow-up using a Wilcoxon
signed rank test of paired tests to assess immunologic/virol-
gic change after genotypic resistance assay and HAART regi-
men change in patients with VF. Statistical analysis was per-
formed using SAS� version 9.1 (SAS Institute, Inc., Cary, NC,
U.S.A.) and considered significant in cases of P<0.05. 
RESULTS
Baseline clinical characteristics 
Thirty-nine patients (95.1%) among 41 were male and the
mean age was 41.9±11.26 yr-old (Table 1). Most isolates
observed were HIV-1 subtype B (38/41, 92.7%); 2 cases were
isolates of subtype AG, and 1 was a subtype AG/G isolate.
Mean HAART duration was 45.3±27.5 months and the
mean number of exposed HAART regimens before genotyp-
ic resistance assay referral was 2.22±1.24. Suboptimal com-
pliance was documented in 11 patients (26.8%) and these
cases were associated with drug adverse reactions in most cases.
The median baseline CD4+ T cell count and log viral load
was 168 cells/μL (interquartile range [IQR], 62-253) and 4.65
copies/mL (IQR, 4.18-5.00), respectively. 
HAART regimen and immunologic/virolgic data after 
regimen change
When genotypic resistance assays were referred, 23 (56.1%)
Genotypic resistance
assay referral (n=80)
Viral load <1,000 copies/mL
(n=11)
HAART less than 6 months
before resistance assay (n=3)
Insufficient for virologic failure*
(n=2)
F/U loss or data not-available after
resistance assay (n=16)
Maintain HAART regimen after
resistance assay (n=7)
HAART regimen change after
resistance assay (n=41)
Fig. 1. Eligible case selection for analysis of virologic and immuno-
logic response after genotypic resistance assay and HAART reg-
imen change in virologic failure patients. 
*Virologic failure was defined as log value of ≥3 in viral loads occur-
ring more than twice during 6 months prior to resistance assay
referral.
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Characteristics Value Characteristics Value
Mean age (yr) 41.9±11.26
Male sex, number of patients (%) 39 (95.1)
Mean prior HAART duration (month) 45.3±27.5
Mean baseline CD4+ T cell count (cells/μL) 195±155
Mean baseline log viral load (copies/mL) 4.60±0.72
Mean 6 month follow up CD4+ T cell count (cells/μL) 355±223
Mean 6 month follow up log viral load (copies/mL) 2.03±1.36
Baseline HAART regimen before genotypic resistance assay, 
number of patients (%)
PI based 23 (56.1)
NNRTI based 16 (39.0)
PI and NNRTI based 2 (4.9)
New HAART regimen after genotypic resistance assay, 
number of patients (%)
PI based 24 (58.5)
NNRTI based 12 (29.3)
PI and NNRTI based 4 (9.8)
Triple NRTI 1 (2.4)
Frequently observed resistance associated mutations, 



















Table 1. Characteristics and frequently observed resistance associated mutations of the 41 patients who changed HAART regimen


























Antiretroviral resistance associated 
mutations (RT/PR)�
1 38 M 78 Suboptimal S/K/E Z/L/K 41L, 103N, 181C, 215Y, 219N/32I, 46I, 54V 11 68 293,000 3,860
2 60 M 19 Optimal Z/L/N S/K/E 41L, 184V/30N 438 663 6,940 <25
3 30 M 71 Suboptimal Z/L/E L/A/AT 70T, 75T, 151M, 179D, 188L/- 24 15 146,000 616,000
4 44 M 24 Suboptimal D/L/N L/K/E 41L, 184V, 210W, 215Y/46I, 90M 4 6 620,000 150
5 47 M 54 Optimal Z/L/N D/S/E 184V/46I, 84V 699 895 3,310 <25
6 62 M 49 Optimal Z/A/K A/K/E 67N, 70R, 184V, 215F, 219E/46I, 54V, 84V, 88D 456 702 29,000 <25
7 36 M 55 Optimal D/L/I L/S/E 184V/90M 11 30 4,800,000 280,000
8 36 M 56 Optimal Z/L/N Z/L/E 184V/30N 241 508 15,000 <25
9 29 M 18 Optimal Z/L/E Z/L/K 41L, 103N, 184I, 215Y, 230L/- 174 537 33,000 <25
10 55 M 42 Optimal L/S/N L/AT/E 41L, 151M, 184V, 215Y/30N, 88D 87 487 35,000 <40
11 39 M 42 Suboptimal L/K/E Z/L/A/K 103N, 184V, 225H/46I, 54V, 82A 142 181 190,000 551
12 32 M 32 Suboptimal Z/L/N D/S/K 103N, 184V/30N, 88D 345 623 2,120 57
13 54 M 18 Optimal Z/L/AT Z/L/K 184V/50L 180 287 41,000 663
14 34 M 7 Optimal L/S/E Z/D/K 103R, 179D, 184V, 190A/- 60 186 100,000 <40
15 24 M 20 Suboptimal L/S/N Z/S/K 75A, 103R, 179D, 184V/30N, 88D  293 425 15,000 48
16 44 M 28 Optimal L/S/E D/L/K 103N, 184V, 188L, 215Y/- 226 531 200,000 <40
17 30 M 19 Optimal D/L/N S/K/E 184V/30N 220 430 12,000 <25
18 46 M 24 Optimal Z/L/E D/S/AT 118I, 184V, 190S/- 229 266 21,000 28
19 56 M 22 Optimal Z/L/N Z/L/E 184V/30N 44 329 15,000 <25
20 58 M 8 Optimal Z/L/N Z/S/E 184V/30N, 46L 548 1,011 21,000 112
21 66 M 13 Optimal Z/L/E Z/L/K 41L, 103N, 184V, 215Y/- 132 344 110,000 <25
22 23 M 21 Optimal Z/L/E Z/L/K 103R, 179D, 184V, 188L/- 150 407 76,200 600
23 57 M 10 Optimal Z/L/E Z/L/K 103N, 184V/- 168 323 6,900 <25
24 43 M 89 Suboptimal D/S/E L/S/AT 41L, 62V, 74V, 75T, 103R, 179D, 181C, 190A, 77 259 21,600 60
210W, 215Y/-
Table 2. Antiretroviral resistance associated mutations and changes in HAART regimen, immunologic/virologic data  
(Continued to the next page)
*Mutations observed in less than 10% of patients were not shown in the Table. These mutations include Y188L, L90M, L74V, V118I, I84V, L100I, Y181C,
Q151M, and V32I. 
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patients were taking a protease inhibitor (PI) based regimen
and 16 patients were taking a non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) based regimen. Two patients
were taking HAART regimen that included both PI and
NNRTI. The most frequently prescribed HAART regimen
was zidovudine (AZT)/lamivudine (3TC)/nelfinavir (NFV)
(9/41, 22.0%) followed by AZT/3TC/efavirenz (EFV) (8/41,
19.5%), 3TC/stavudine (d4T)/EFV (4/41, 9.8%), 3TC/d4T/
lopinavir/ritonavir (Kal) (3/41, 7.3%), and didanosine (ddI)/
3TC/EFV (3/41, 7.3%) (Table 2). After genotypic resistance
assay, 24 patients changed their HAART regimen to a PI
based regimen, and NNRTI based regimen or PI+NNRTI
based regimens were prescribed to 12 and 4 patients, respec-
tively. AZT/3TC/Kal (9/41, 22.0%) was the most frequent-
ly prescribed regimen after genotypic resistance assay in VF
patients. Six months after genotypic resistance assay and HA-
ART regimen change, median CD4+ T cell count and log
viral loads were 276 cells/μL (IQR, 153-381) and 1.91 copies/
mL (IQR, 1.10-3.60) respectively, and both immunologic
and virologic improvement were statistically significant com-
pared to baseline values (P<0.001). Twenty-six patients (63.4
%) accomplished a viral load <400 copies/mL 6 months after
regimen change.
Antiretroviral resistance associated mutations and 
susceptibility for HAART regimen
M184V/I mutation was observed in 36 patients (87.7%)
followed by T215Y/F (17/41, 41.5%) and M46I/L (14/41,
34.2%). M41L, I54V, D30N, and V82A/T/S were observed
in more than 10 patients and K103N (10/41, 24.4%) was


























Antiretroviral resistance associated 
mutations (RT/PR)
25 39 M 97 Optimal Z/L/K D/A/E 67N, 70R, 103R, 118I, 184V, 210M, 264 320 1,800 <25
219Q/24I, 46L, 53L, 54V, 82A 
26 40 M 83 Optimal D/S/K Z/D/L/E 67N, 70R, 215F, 219Q/46I, 54V, 82A 324 610 94,600 <40
27 39 M 78 Optimal D/L/E D/L/K 41L, 74V, 100I, 103N, 118I, 184V, 210W,  249 403 3,300 <25
215Y, 219N/-
28 44 M 36 Suboptimal Z/L/E Z/L/K 41L, 67N, 70R, 75M, 101E 184V, 190S, 62 296 50,000 <25
210W, 215Y, 219Q/-
29 41 M 27 Optimal D/L/E L/S/AT 41L, 74V, 100I, 103N, 184V, 210W, 215Y/82A 122 217 100,000 180,000
30 31 M 85 Optimal L/S/K Z/D/A 70R, 184V/46I, 54V, 82S 44 157 13,000 <40
31 39 M 85 Optimal L/S/K L/S/E 184V/46L, 54V, 82A 196 208 120,000 1,800
32 34 M 86 Optimal Z/L/K D/A/E 41L, 184V, 215Y/33F, 46I, 54V, 82A 228 257 45,000 1,400
33 44 M 90 Suboptimal L/S/I Z/A/AT 41L, 44D, 67N, 118I, 184V, 210W, 215Y, 304 381 186,000 14,000
219R/46L, 54V, 82A, 90M 
34 30 M 91 Suboptimal D/L/E Z/L/AT 74V, 100I, 103N, 184V, 219N/- 47 351 100,000 <40
35 46 M 36 Optimal Z/L/N Z/D/I 67N, 70R, 184V, 215Y, 219Q/30N, 88D 39 94 90,000 <25
36 67 M 57 Suboptimal L/S/E Z/D/K 179E, 184V, 188L, 215F/54V, 82T, 90M 230 239 8,800 <25
37 39 M 30 Optimal L/S/K D/L/E 74V, 184V/46I, 54V, 82A 135 265 82,000 2,800
38 45 F 49 Optimal D/L/K Z/D/E 184V/46I, 47V, 84V 253 322 80,000 <25
39 29 M 37 Optimal Z/L/E D/S/K 67N, 70R, 106M, 184V, 190A, 215Y, 219E, 227L/- 17 136 600,000 82
40 34 F 35 Optimal Z/L/N Z/L/K 184V/30N, 88D 344 471 6,900 <25
41 34 M 36 Optimal L/S/E L/S/K 103N, 179E, 184V/- 76 232 46,000 <25
42 54 M 86 Suboptimal D/K/E →� 74V, 184V, 100I, 103N/ 46I, 54V, 82A 195 13 6,500 25,000
43 28 M 29 Optimal Z/L/I → 184V/- 263 367 9,000 12,000
44 55 M 11 Optimal Z/L/I → 184V/- 368 340 1,800 420
45 45 F 34 Optimal Z/A/K → -/- 228 87 8,300 79,000
46 38 M 65 Suboptimal Z/L/K → 41L, 67N, 69N, 70R, 184V, 215F, 219Q, 120 27 160,000 3,130,000
101P, 188L /46I, 54V, 82F, 90M
47 35 M 23 Optimal D/L/K → 184V, 179D/- 150 269 8,900 41,800
48 38 M 9 Optimal Z/L/K → -/- 180 210 4,200 2,500
Table 2. (Continued from the previous page) Antiretroviral resistance associated mutations and changes in HAART regimen, immu-
nologic/virologic data  
*Antiretroviral drug is displayed in boldface if its susceptibility was interpreted as intermediate to high level resistance by Stanford HIV Resistance
Database; 
�
‘-’ denotes wild type. Amino acid variations were not displayed in the table if they were interpreted as protease inhibitor minor mutations by
Stanford HIV Resistance Database; 
�
‘→’ denotes that the HAART regimen was not changed after resistance assay.
M, male; F, female; Mo., month; RT, reverse transcriptase; PR, protease; F/U, Follow up; S, stavudine; K, lopinavir/ritonavir; E, efavirenz; Z, zidovudine;
L, lamivudine; N, nelfinavir; A, abacavir; AT, atazanavir; D, didanosine; I, indinavir.
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In regards to the susceptibility for respective drug included
in HAART regimen with VF, almost all patients taking 3TC
(36/37), EFV (18/18), NFV (12/12), and Kal (10/10) revealed
intermediate to high level resistance while susceptibilities
for AZT (11/20) and d4T (8/13) were preserved in more than
half patients who were taking these drugs. Susceptibility for
ddI was maintained in 3 among 9 patients (33.3%). Regard-
ing to the number of susceptible drugs among HAART reg-
imen prior to resistance assay referral, 40 patients (97.6%)
were taking 1 or no susceptible antiretroviral drugs before
genotypic assay and all prescribed antiretroviral drugs were
non-susceptible in 18 patients (43.9%). After resistance assay,
2 or more antiretroviral drugs in new HAART regimen were
susceptible in 31 patients (75.6%).
DISCUSSION
The genotypic resistance assay has become the standard of
care in the treatment of HIV-1 infected patients especially
in cases of VF, and its efficacy has been proven by numerous
studies as well as the phenotypic resistance assay. Although
Luca et al. (14) observed variations in the prediction of sub-
sequent antiretroviral treatment outcomes among different
genotypic resistance interpretation systems of rules-based
algorithms, we believe that these systems will evolve through
the accumulation of data from treatment experience.
During our study period, PI based regimens comprised
56.1% (23/41) of patients with VF and NFV was the most
commonly prescribed PI (12/23, 52.2%). Among these 23
patients with a PI based regimen, 12 patients (52.2%) changed
to a NNRTI based regimen while 6 patients (26.1%) main-
tained PI based regimens substituted with newer PIs. How-
ever, all 16 patients that failed the NNRTI based regimen
changed to a PI based regimen. This implies that invariable
cross resistance among NNRTIs affected HAART regimen
selection in these patients.
The most frequently prescribed nucleoside reverse transcrip-
tase inhibitor (NRTI) backbone in VF patients was AZT/3TC
(20/41, 48.8%). During our study period, available NRTIs
in the Republic of Korea were AZT, 3TC, d4T, ddI and aba-
cavir. Almost all patients were taking 3TC in our study group
and most isolates of these patients revealed resistance to 3TC
associated with M184V/I mutation. It is known that pres-
ence of the M184V mutation might delay or prevent emer-
gence of thymidine analogue mutations (TAM) (15, 16). In
our study group, 31 patients were prescribed with thymi-
dine analogues (AZT or d4T) with 3TC. Among them, all
revealed intermediate to high-level resistance to 3TC while
only 10 patients (32.3%) revealed non-susceptibility to thymi-
dine analogues and this phenomenon was observed in both
PI based regimens (5/19) and NNRTI based regimens (5/10).
Except for thymidine analogues and ddI, most antiretroviral
drugs involved in failing HAART regimens proved to be non-
susceptible as described above. Considering that tenofovir is
not available and a combination of ddI and d4T is not recom-
mended on account of toxicity (13), optimizing the NRTI
backbone might not be feasible in patients with VF. Further-
more, AZT is frequently complicated with bone marrow sup-
pression.
Six months after genotypic resistance assay and HAART
regimen change, CD4+ T cell count and log viral load im-
proved significantly. While 40 patients were taking 1 or no
susceptible antiretroviral drugs before genotypic assay, 31
patients (75.6%) were prescribed new regimens containing
2 or more susceptible antiretroviral drugs after resistance assay.
However, the response for HAART is influenced by many
other factors such as drug compliance, as well as resistance.
Our study included 11 patients with suboptimal compliance
before genotypic resistance assay and most cases were associ-
ated with drug adverse effects. The immunologic and viro-
logic improvement observed in our study group might be
associated with a compliance change. However, neither base-
line immunologic/virologic parameters nor improvement of
them 6 months after HAART regimen change were differ-
ent according to drug compliance before resistance assay (non-
parametric analysis, data not shown). This indirectly implies
that the influence of compliance on immunologic/virologic
improvement after resistance assay was limited in our study
group. Furthermore, suboptimal compliance is one of the
crucial conditions for antiretroviral resistance acquisition and
resistance assay might be quite beneficial for these patients
(17). In our study group, 26 patients (63.4%) accomplished
viral load <400 copies/mL 6 months after regimen change
and it is comparable with that of antiretroviral naive patients
starting HAART (103/141, 73%) as previously reported in
the same country (18). We supposed that our study group
revealed fair results considering that almost all patients har-
bored strains with resistance to 2 or more classes of antiretro-
viral drugs. 
As we described before, 7 patients with VF did not change
their HAART regimens after genotypic resistance assay (Table
2). This group consisted of 2 patients with multiple resis-
tances and 5 patients with limited resistance profiles. Case
46, who was taking AZT/3TC/Kal, revealed a high-level resis-
tance to all antiretroviral drugs analyzed by Stanford database
(version 4.2.4). Case 42, who was taking ddI/Kal/EFV, also
revealed a high-level resistance to all antiretroviral drugs except
for AZT, d4T, and tenofovir which was not available during
our study period. However, the patient had been not toler-
ated AZT before resistance assay referral because of neutrope-
nia and d4T was included in the prior VF HAART regimen.
The CD4+ T cell count and viral load aggravated in these
patients after maintenance of the same HAART regimen for
6 months. For the other 5 patients, equal or less than one anti-
retroviral drug revealed resistance among prescribed HAART
regimen. In these patients, the CD4+ T cell count/viral load
revealed various progresses after maintenance of same HAART
. .
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regimen for 6 months. In a comparison of the HAART reg-
imen change group and HAART regimen non-change group
after resistance assay, increases in both the median CD4+ T
cell count and decreases in median log viral load were more
favorable in the HAART regimen change group (P=0.019
and P<0.001, respectively. Wicoxon rank sum test, data not
shown). We supposed this was partially due to the character-
istics of the study groups as well as HAART regimen change.
However, it may not dwindle the efficacy of genotypic resis-
tance assay in VF. A randomized study comparing HAART
regimen change with resistance assay results and HAART
regimen change with only prior HAART history and viro-
logical/immunological responses would prove the efficacy of
resistance assay more effectively, but it was not possible to
analyze our data in this manner. 
This study has a few limitations. First, this study includes
a small number of patients and only short term follow-up
data were available. However, this study will help to identi-
fy resistance patterns and clinical responses after genotypic
resistance assay in Korean HIV-I infected patients with VF.
Second, patients with suboptimal compliance were included
in analysis and this factor might have confounded the bene-
fit of resistance testing, although it was not significant as
mentioned above. However, considering the close relation-
ship between suboptimal compliance and antiretroviral resis-
tance acquisition, we believe that it might warrant vigorous
resistance testing for these patients as well as patients with
fair compliance.
In conclusion, many Korean HIV-1 infected patients with
VF are harboring strains with multiple genotypic resistance
mutations and immunologic/virologic parameters are improv-
ed significantly after genotypic resistance assay and HAART
regimen change.
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